BridgeBio Pharma (BBIO) Shares Outstanding (Weighted Average) (2017 - 2026)
BridgeBio Pharma recorded quarterly Shares Outstanding (Weighted Average) of $194.8 million in Q1 2026, up 1.7% quarter-over-quarter from $191.5 million in Q4 2025, and up 2.44% year-over-year from $190.1 million in Q1 2025.
BridgeBio Pharma's Shares Outstanding (Weighted Average) history runs 10 years deep, the most recent figure standing at $194.8 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Weighted Average) rose 2.44% year-over-year to $194.8 million; the TTM figure through Mar 2026 stood at $194.8 million (up 2.44% YoY), while the FY2025 annual figure was $191.5 million, up 2.93% from the prior year.
- Shares Outstanding (Weighted Average) came in at $194.8 million for Q1 2026 at BridgeBio Pharma, up from $191.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $194.8 million in Q1 2026 to a low of $145.9 million in Q1 2022.
- A 5-year average of $171.5 million and a median of $178.7 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- Across the five-year window, Shares Outstanding (Weighted Average) increased 19.75% in 2024 and gained 1.56% in 2025, its largest moves.
- BridgeBio Pharma's Shares Outstanding (Weighted Average) stood at $147.5 million in 2022, then advanced by 10.39% to $162.8 million in 2023, then advanced by 14.3% to $186.1 million in 2024, then rose by 2.93% to $191.5 million in 2025, then advanced by 1.7% to $194.8 million in 2026.
- According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $194.8 million, $191.5 million, and $191.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | 194.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 194.79 Mn |
| Dec 31, 2025 | 191.53 Mn |
| Sep 30, 2025 | 191.85 Mn |
| Jun 30, 2025 | 190.52 Mn |
| Mar 31, 2025 | 190.15 Mn |
| Dec 31, 2024 | 186.08 Mn |
| Sep 30, 2024 | 184.95 Mn |
| Jun 30, 2024 | 187.59 Mn |
| Mar 31, 2024 | 178.71 Mn |
| Dec 31, 2023 | 162.79 Mn |
| Sep 30, 2023 | 158.89 Mn |
| Jun 30, 2023 | 156.65 Mn |
| Mar 31, 2023 | 152.65 Mn |
| Dec 31, 2022 | 147.47 Mn |
| Sep 30, 2022 | 147.94 Mn |
| Jun 30, 2022 | 146.29 Mn |
| Mar 31, 2022 | 145.88 Mn |
| Dec 31, 2021 | 144.36 Mn |
| Sep 30, 2021 | 144.04 Mn |
| Jun 30, 2021 | 142.71 Mn |
| Mar 31, 2021 | 138.63 Mn |
| Dec 31, 2020 | 118.00 Mn |
| Sep 30, 2020 | 117.66 Mn |
| Jun 30, 2020 | 117.01 Mn |
| Mar 31, 2020 | 117.80 Mn |
| Dec 31, 2019 | 105.10 Mn |
| Sep 30, 2019 | 100.86 Mn |
| Jun 30, 2019 | 92.89 Mn |
| Mar 31, 2019 | 92.33 Mn |
| Dec 31, 2018 | 61.77 Mn |
| Sep 30, 2018 | 57.44 Mn |
| Jun 30, 2018 | 17.82 Mn |
| Dec 31, 2017 | 30.60 Mn |